Practical management of myelofibrosis with ruxolitinib

Ho, P.J., Marlton, P., Tam, C., Stevenson, W., Ritchie, D., Bird, R., Dunlop, L.C., Durrant, S. and Ross, D.M. (2015) Practical management of myelofibrosis with ruxolitinib. Internal Medicine Journal, 45 12: 1221-1230. doi:10.1111/imj.12921


Author Ho, P.J.
Marlton, P.
Tam, C.
Stevenson, W.
Ritchie, D.
Bird, R.
Dunlop, L.C.
Durrant, S.
Ross, D.M.
Title Practical management of myelofibrosis with ruxolitinib
Journal name Internal Medicine Journal   Check publisher's open access policy
ISSN 1445-5994
1444-0903
Publication date 2015-12-09
Year available 2015
Sub-type Article (original research)
DOI 10.1111/imj.12921
Open Access Status Not yet assessed
Volume 45
Issue 12
Start page 1221
End page 1230
Total pages 10
Place of publication Richmond, Victoria, Australia
Publisher Wiley-Blackwell Publishing
Collection year 2016
Language eng
Formatted abstract
Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease. Around 50% of patients with myelofibrosis have the JAK2V617F mutation, but almost all patients have aberrant activation of the JAK-STAT signalling pathway. Recent efforts have focussed on the clinical use of JAK2 inhibitors to treat myelofibrosis. In this article, we present our recommendations for the practical management of myelofibrosis with ruxolitinib, a selective inhibitor of both JAK1 and JAK2. Ruxolitinib can significantly improve the quality of life of patients with myelofibrosis. There is also increasing evidence of a positive impact on survival. Consistent with the physiological role of JAK signalling the major toxicity of ruxolitinib is cytopenia. Managing cytopenia is key to maximising the therapeutic benefit of ruxolitinib. Further research into the safety of ruxolitinib in patients with thrombocytopenia is warranted, as is its role in special subgroups of patients, such as those undergoing stem cell transplantation and those experiencing thrombosis as a major manifestation of myelofibrosis.
Keyword Ruxolitinib
Myelofibrosis
Therapeutics
Treatment outcome
Side-effects
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 29 Dec 2015, 00:40:33 EST by System User on behalf of Scholarly Communication and Digitisation Service